Clinical characteristics and risk factors for mortality in cancer patients with COVID-19.
10.1007/s11684-021-0845-6
- Author:
Junnan LIANG
1
;
Guannan JIN
2
;
Tongtong LIU
3
;
Jingyuan WEN
1
;
Ganxun LI
1
;
Lin CHEN
1
;
Wei WANG
1
;
Yuwei WANG
1
;
Wei LIAO
1
;
Jia SONG
1
;
Zeyang DING
4
;
Xiao-Ping CHEN
5
;
Bixiang ZHANG
6
Author Information
1. Hepatic Surgery Center, Liver Cancer Institute, and Hubei Key Laboratory of HPB Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
2. Department of Internal Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
3. Tongji Multidisciplinary Team for Treating COVID-19 (TTTC), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
4. Hepatic Surgery Center, Liver Cancer Institute, and Hubei Key Laboratory of HPB Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. dingzeyang@hust.edu.cn.
5. Hepatic Surgery Center, Liver Cancer Institute, and Hubei Key Laboratory of HPB Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. chenxpchenxp@163.com.
6. Hepatic Surgery Center, Liver Cancer Institute, and Hubei Key Laboratory of HPB Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. bixiangzhang@hust.edu.cn.
- Publication Type:Journal Article
- Keywords:
COVID-19;
SARS-CoV-2;
cancer;
mortality;
risk factor
- MeSH:
COVID-19;
Hospital Mortality;
Humans;
Neoplasms;
Prognosis;
Retrospective Studies;
Risk Factors;
SARS-CoV-2
- From:
Frontiers of Medicine
2021;15(2):264-274
- CountryChina
- Language:English
-
Abstract:
Patients with cancer are at increased risk of severe infections. From a cohort including 3060 patients with confirmed COVID-19, 109 (3.4%) cancer patients were included in this study. Among them, 23 (21.1%) patients died in the hospital. Cancer patients, especially those with hematological malignancies (41.6%), urinary carcinoma (35.7%), malignancies of the digestive system (33.3%), gynecological malignancies (20%), and lung cancer (14.3%), had a much higher mortality than patients without cancer. A total of 19 (17.4%) cancer patients were infected in the hospital. The clinical characteristics of deceased cancer patients were compared with those of recovered cancer patients. Multivariate Cox regression analysis indicated that a Nutritional Risk Screening (NRS2002) score ⩾ 3 (adjusted hazard ratio (HR) 11.00; 95% confidence interval (CI) 4.60-26.32; P < 0.001), high-risk type (adjusted HR 18.81; 95% CI 4.21-83.93; P < 0.001), tumor stage IV (adjusted HR 4.26; 95% CI 2.34-7.75; P < 0.001), and recent adjuvant therapy (< 1 month) (adjusted HR 3.16; 95% CI 1.75-5.70; P < 0.01) were independent risk factors for in-hospital death after adjusting for age, comorbidities, D-dimer, and lymphocyte count. In conclusion, cancer patients showed a higher risk of COVID-19 infection with a poorer prognosis than patients without cancer. Cancer patients with high-risk tumor, NRS2002 score ⩾ 3, advanced tumor stage, and recent adjuvant therapy (< 1 month) may have high risk of mortality.
